Clinical Trials @ RGW

bars-index-header-blue-1
bars-index-header-orange

Clinical Trials @ RGW

Wet Macular Degeneration

CANDELA (Sponsor: Regeneron Pharmaceuticals)
2020-Present

Clinical Trial Protocol Number: VGFTe (HD)-AMD-1905

A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration.

COAST (Sponsor: Opthea)
2018-Present

Clinical Trial Protocol Number: OPT-302-1005

A Phase 3, Multicenter, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

MERLIN (Sponsor: Novartis Pharmaceuticals Corp.)
2019-Present

Clinical Trial Protocol Number: CRTH258AUS04

A Multicenter, Randomized, Double-Masked Phase 3a Study To Assess The Safety And Efficacy Of Brolucizumab 6mg Q4 weeks Compared To Aflibercept 2mg Q4 weeks In Patients With Neovascular Age-Related Macular Degeneration With Persistent Retinal Fluid.

PORTAL (Sponsor: F. Hoffmann-La Roche Ltd.)
2018-Present

Clinical Trial Protocol Number: GR40549

A Multicenter, Open-Label Extension Study To Evaluate The Long-Term Safety And Tolerability Of The Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration.

TENAYA (Sponsor: F. Hoffmann-La Roche Ltd.)
2018-Present

Clinical Trial Protocol Number: GR40306

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study To Evaluate The Efficacy And Safety Of Faricimab in Patients With Neovascular Age-Related Macular Degeneration.

SAMSUNG SB-15 (Sponsor: Samsung Bioepis Co., Ltd.)
2020-Present

Clinical Trial Protocol Number: SB15

A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB15 (proposed aflibercept biosimilar) and Eylea® in Subjects with Neovascular Age-related Macular Degeneration

Dry Macular Degeneration

DERBY and OAKS (Sponsor: Apellis Pharmaceuticals)
2018-Present

Clinical Trial Protocol Numbers: APL-303 and APL-304

A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).

SAGA (Sponsor: Alkeus Pharmaceuticals, Inc.)
2018-Present

Clinical Trial Protocol Number: ALK-001

A Phase 2/3 Multicenter, Randomized, Double-Masked, Parallel-Group, Placebo-Controlled Study To Investigate The Safety, Pharmacokinetics, Tolerability, And Efficacy Of ALK-001 In Geographic Atrophy Secondary To Age-Related Macular Degeneration.

Gather2 (Sponsor: IVERIC Bio)
2020-Present

Clinical Trial Protocol Number: ISEE2008

A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED, CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL ADMINISTRATION OF ZIMURA™, (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION

Gallego (Sponsor: Genentech, Inc.)
2019-Present

Clinical Trial Protocol Number: GR40973

A PHASE II, MULTICENTER, RANDOMIZED, SINGLE-MASKED, SHAM−CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND EFFICACY OF INTRAVITREAL INJECTIONS OF FHTR2163 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

Diabetic Macular Edema

Rhone-X (Sponsor: Genentech)
2021-Current

Clinical Trial Protocol Number: GR41987

A Multicenter, Open-label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with Diabetic Macular Edema

Pavillion (Sponsor: Genentech)
2020-Current

Clinical Trial Protocol Number: GR41675

A Phase 3, Multicenter, Randomized study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in patients with Diabetic Retinopathy

PAGODA (Sponsor: F. Hoffmann-La Roche Ltd)
2018-Present

Clinical Trial Protocol Number: GR40550

A Phase II, Multicenter, Randomized, Visual Assessor Masked, Active Comparator Study of The Efficacy, Safety, And Pharmacokinetics of The Port Delivery System With Ranibizumab in patients with Diabetic Macular Edema.

Diabetic Retinopathy

FOCUS (Sponsor: Novo Nordisk)
2019-Present

Clinical Trial Protocol Number: NN9535-4352

This Trial Is A Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Trial To Assess The Long-Term Effects Of Treatment With Semaglutide Compared To Placebo, Both Added To Standard-Of-Care, On Diabetic Retinopathy Development And Progression In Subjects With Type 2 Diabetes.

Retinal Vein Occlusion

COMINO (Sponsor: Genentech)
2021-Current

Clinical Trial Protocol Number: GR41986

A Phase 3, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled study to evaluate the Efficacy and Safety of Faricimab in patients with Macular Edema Secondary to Central Retina or Hemiretinal Vein Occlusion

Beacon (Sponsor: Kodiak)
2021-Current

Clinical Trial Protocol Number: KS301P103

A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion

Loading ...

©All Rights Reserved. RGW 2021